|1.||Edgerton, V Reggie: 4 articles (07/2008 - 12/2005)|
|2.||Roy, Roland R: 4 articles (07/2008 - 12/2005)|
|3.||Ichiyama, Ronaldo M: 2 articles (07/2008 - 06/2008)|
|4.||Zhong, Hui: 2 articles (07/2008 - 06/2008)|
|5.||Otoshi, Chad K: 2 articles (10/2006 - 12/2005)|
|6.||Fong, Andy J: 2 articles (10/2006 - 12/2005)|
|7.||Burdick, Joel W: 2 articles (10/2006 - 12/2005)|
|8.||Cai, Lance L: 2 articles (10/2006 - 12/2005)|
|9.||Kaur, Gurpreet: 2 articles (07/2002 - 02/2002)|
|10.||Kulkarni, Shrinivas K: 2 articles (07/2002 - 02/2002)|
09/01/1990 - "Both normal and genetically dystonic (dt) rats show a high-frequency forepaw tremor in response to systemic administration of the serotonin (5-HT) agonist quipazine at 8 days of age. "
07/01/1976 - "Both TRH and quipazine (2.5-25 mg/kg) were found to restore and to intensify the oxotremorine-induced tremor in mice when injected i.p. "
05/01/1980 - "2 In rats pretreated with pargyline, the behavioural syndrome induced by DMT differed from that induced by L-tryptophan or quipazine, in the lack of forepaw treading and head-weaving and in the presence of only mild tremor. "
09/30/1983 - "Agents effective in attenuating the frequency of tremor were chlordiazepoxide, muscimol, and mecamylamine; quipazine exacerbated the tremor. "
07/01/1985 - "As regards behavioural effects, tremor induced by quipazine was present from the first postnatal day and was antagonized by methysergide, but not by p-chlorophenylalanine (PCPA) or pretreatment with 5,7-dihydroxytryptamine (5,7-DHT). "
01/01/1990 - "Evidence for 5-HT2 receptor mediation in quipazine anorexia."
05/01/1984 - "We found quipazine, a putative 5-HT postsynaptic agonist, in a dose range of 2-10 mg/kg, to be no more effective in producing anorexia in lesion rats compared to controls. "
01/01/1990 - "These results suggest that the quipazine anorexia is largely mediating through 5-HT2 receptors, although the effect of pimozide remains to be explained. "
01/01/1986 - "RU-24969 and quipazine) decrease feeding and cause anorexia. "
05/01/1985 - "Comparison of anorexia and motor disruption by cyclazocine and quipazine."
07/12/2002 - "Further, treatment with both fluoxetine (10 mg/kg, i.p.) and quipazine (5 mg/kg, i.p.) significantly reversed progesterone-induced hyperphagia, depression and algesia in the female mice. "
07/12/2002 - "Further, seganserin, 2 mg/kg, i.p., significantly reversed the suppressive effect of fluoxetine and quipazine on progesterone-induced hyperphagia, depression and algesia in hot-plate test. "
02/01/2002 - "The study further investigated the central dopamine and serotonergic receptor involvement in clozapine-induced hyperphagia using SKF 38393, quinpirole and quipazine. "
02/01/2002 - "Further, clozapine-induced hyperphagia was significantly (P<.05) reversed after treatment with SKF 38393 (dopamine D1 agonist), quinpirole (dopamine D2 agonist) and quipazine (5-HT1B, 5-HT2 and 5-HT3 agonist). "
05/06/1985 - "It was found that anorectics that act through a serotoninergic mechanism, i.e., d- and d-l-fenfluramine, p-chloroamphetamine, quipazine and fluoxetine antagonize both insulin- and 2-DG-induced overeating, while anorectics acting through the dopaminergic system, i.e., d-amphetamine, diethylpropion, lisuride, bromocriptine and mazindol, antagonize the hyperphagia induced by 2-DG but not that induced by insulin. "
07/01/1995 - "Quipazine increased plasma PRL levels from 26.8 +/- 7.1 ng/ml at Time 0 to a peak value of 148.1 +/- 31.4 ng/ml 2 hr after infection. "
10/01/2004 - "The present study sought to provide more insights into postnatal virus-associated alterations in 5-HT neurotransmission by evaluating the density of 5-HT1a receptors in the hippocampus and 5-HT2a receptors in the cortex, regional 5-HT tissue concentrations, behavioral responses to a 5-HT agonist, quipazine, and numbers of neurons in specific subfields of the hippocampus on days 7, 14, and 30 after neonatal BDV infection in Lewis rats. "
|1.||Serotonin (5 Hydroxytryptamine)
|8.||Serotonin Receptor Agonists (Serotonin Receptor Agonist)
|2.||Induced Hyperthermia (Thermotherapy)